Abbott

Nachrichten

Reuters - vor 4 Tagen

Abbott accuses one of its former scientists of trade-secrets theft in US court

Abbott accuses one of its former scientists of trade-secrets theft in US court By Mike Scarcella May 31 (Reuters) - Healthcare company Abbott Laboratories ABT.N on Tuesday sued one of its former scientists, accusing him in U.S. court of "secretly downloading" sensitive corporate files containing competitive information about nutrition products. The lawsuit in Chicago federal court alleged Roger Tyre committed "flagrant misconduct" prior to leaving Illinois-based Abbott, which sells the Ensure br

Reuters - vor 1 Woche

Wall Street Journal - May 25

PRESS DIGEST - Wall Street Journal - May 25 May 25 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - Ratings agency Fitch put the United States' credit on watch for a possible downgrade, raising the stakes as talks over the country's debt ceiling go down to the wire, and adding to the jitters in global markets.

Reuters - vor 2 Wochen

Abbott, baby formula makers face FTC probe for potential collusion

UPDATE 3-Abbott, baby formula makers face FTC probe for potential collusion Adds Abbott comment in new paragraph 8 May 24 (Reuters) - The U.S. Federal Trade Commission ( FTC) is probing whether Abbott Laboratories ABT.N and other companies that make baby formula colluded in bidding on state contracts, according to a document posted on the agency's website.

Reuters - vor 2 Wochen

Abbott, other formula makers face FTC investigation for collusion - WSJ

Abbott, other formula makers face FTC investigation for collusion - WSJ May 24 (Reuters) - The U.S. Federal Trade Commission is investigating whether baby-formula makers colluded on bids for attractive state contracts, the Wall Street Journal reported on Wednesday. The FTC said it is looking into whether Abbott Laboratories ABT.N and other formula manufacturers have "engaged in collusion or coordination with any other market participant regarding the bidding" for state contracts, the report said

Reuters - vor 2 Wochen

Baby-Formula Makers Face FTC Investigation For Collusion - WSJ

BRIEF-Baby-Formula Makers Face FTC Investigation For Collusion - WSJ May 24 (Reuters) - BABY-FORMULA MAKERS FACE FTC INVESTIGATION FOR COLLUSION - WSJ FTC IS LOOKING INTO WHETHER ABBOTT AND OTHER FORMULA MANUFACTURERS HAVE ENGAGED IN COLLUSION OR COORDINATION WITH ANY OTHER MARKET PARTICIPANT- WSJ Source text [ https://bit.ly/422DhGr ] Further comp

Reuters - vor 2 Wochen

Judge tosses out some claims in Abbott baby formula litigation

UPDATE 1-Judge tosses out some claims in Abbott baby formula litigation Adds Abbott statement in 11th paragraph By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bac

Reuters - vor 2 Wochen

Judge tosses out some claims in Abbott baby formula litigation

Reuters - vor 2 Wochen

Judge tosses some claims in Abbott baby formula litigation

Judge tosses some claims in Abbott baby formula litigation By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination.

Reuters - vor 2 Wochen

Indian shares recover from weak start on buying at key levels

INDIA STOCKS-Indian shares recover from weak start on buying at key levels Updates levels in paragraph 2, adds index details in paragraphs 3-5, analysts' comments in 6,11, stock moves in paragraphs 7-8 By Bharath Rajeswaran BENGALURU, May 22 (Reuters) - Indian shares recovered from a subdued start on Monday, led by the gains in information technology and pharmaceutical stocks, as investors saw buying opportunities at key levels ahead of the resumption of debt ceiling talks in the United States.

Reuters - vor 2 Wochen

Abbott Unveils Late-Breaking Data Showing Its Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints

BRIEF-Abbott Unveils Late-Breaking Data Showing Its Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints May 20 (Reuters) - Abbott Laboratories ABT.N : ABBOTT UNVEILS LATE-BREAKING DATA SHOWING THE WORLD'S FIRST DUAL-CHAMBER LEADLESS PACEMAKER STUDY MET ALL THREE PRIMARY ENDPOINTS STUDY SUCCESSFULLY MET ALL THREE OF ITS PRIMARY SAFETY AND PERFORMANCE ENDPOINTS ABBOTT'S INVESTIGATIONAL AVEIR DR LEADLESS PACEMAKERS HAVE BEEN SUBMITTED FOR EVALUATION BY U.S.

Reuters - vor 2 Wochen

U.S. STOCKS Stereotaxis, AbbVie, CureVac

BUZZ-U.S. STOCKS ON THE MOVE-Stereotaxis, AbbVie, CureVac Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes erased early gains on Friday as U.S. debt ceiling talks between the White House and House Republican lawmakers were paused, dampening hopes that a deal could be reached soon to avoid a calamitous default.

Reuters - vor 2 Wochen

U.S. STOCKS GoHealth, Hologic, LyondellBasell

BUZZ-U.S. STOCKS ON THE MOVE-GoHealth, Hologic, LyondellBasell Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes erased early gains on Friday as U.S. debt ceiling talks between the White House and House Republican lawmakers were paused, dampening hopes that a deal could be reached soon to avoid a calamitous default.

Reuters - vor 2 Wochen

Stereotaxis And Abbott Announce Global Collaboration Combining Leading Mapping And Robotic Technologies To Improve Treatment Of Abnormal Heart Rhythms

BRIEF-Stereotaxis And Abbott Announce Global Collaboration Combining Leading Mapping And Robotic Technologies To Improve Treatment Of Abnormal Heart Rhythms Stereotaxis Inc STXS.A : STEREOTAXIS AND ABBOTT ANNOUNCE GLOBAL COLLABORATION COMBINING LEADING MAPPING AND ROBOTIC TECHNOLOGIES TO IMPROVE TREATMENT OF ABNORMAL HEART RHYTHMS STEREOTAXIS INC -

Reuters - vor 2 Wochen

Abbott's India arm posts 9.5% rise in fourth-quarter profit

Abbott's India arm posts 9.5% rise in fourth-quarter profit BENGALURU, May 19 (Reuters) - Abbott India Ltd ABOT.NS reported a 9.5% jump in fourth-quarter profit on Friday, helped by strong sales in its mainstay pharmaceuticals segment. Profit for the company, which makes ibuprofen pain-reliever under the brand name Brufen, rose to 2.31 billion rupees ($28.3 million) in the three months ended March 31, from 2.11 billion rupees a year ago, the company said in an exchange filing.

Reuters - vor 2 Wochen

India economic, corporate events on May 19

DIARY-India economic, corporate events on May 19 BENGALURU, May 19 (Reuters) - Diary of India economic, corporate events on May 19. ECONOMIC, CORPORATE .BSE500 EVENTS: RIC Local Start Date Local Time Indicator Name Period Reuters Poll Prior INLOAN=ECI 19 May 2023 17:00 Bank Loan Growth 5 May, w/e 15.9% INDEP=ECI 19 May 2023 17:00 Deposit Growth 5 M

Reuters - vor 2 Wochen

Abbott Receives FDA Clearance For Assert-IQ Insertable Cardiac Monitor To Help Doctors Monitor People's Heart Rhythms Long-Term

BRIEF-Abbott Receives FDA Clearance For Assert-IQ Insertable Cardiac Monitor To Help Doctors Monitor People's Heart Rhythms Long-Term May 18 (Reuters) - Abbott Laboratories ABT.N : ABBOTT RECEIVES FDA CLEARANCE FOR ASSERT-IQ™ INSERTABLE CARDIAC MONITOR TO HELP DOCTORS MONITOR PEOPLE'S HEART RHYTHMS LONG-TERM ABBOTT RECEIVES FDA CLEARANCE FOR ASSE

Reuters - vor 3 Wochen

Abbott Receives FDA Approval For Its Spinal Cord Stimulation Systems To Treat Chronic Back Pain In People Who Have Limited Surgical Options

BRIEF-Abbott Receives FDA Approval For Its Spinal Cord Stimulation Systems To Treat Chronic Back Pain In People Who Have Limited Surgical Options May 16 (Reuters) - Abbott Laboratories ABT.N : ABBOTT RECEIVES FDA APPROVAL FOR ITS SPINAL CORD STIMULATION SYSTEMS TO TREAT CHRONIC BACK PAIN IN PEOPLE WHO HAVE LIMITED SURGICAL OPTIONS ABBOTT LABORATORIES - NEW INDICATION WILL SPAN ACROSS ENTIRETY OF ABBOTT'S SCS PORTFOLIO IN U.S.

Reuters - vor 3 Wochen

Abbott Labs is sued over PediaSure height claims

UPDATE 1-Abbott Labs is sued over PediaSure height claims Bronx woman sues over Abbott's 'clinically proven' claim Lawsuit says plaintiff's grandson did not gain height Abbott says lawsuit is without merit Adds Abbott statement in paragraph 6 By Jonathan Stempel NEW YORK, May 15 (Reuters) - A New York City woman sued Abbott Laboratories ABT.N on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase child

Reuters - vor 3 Wochen

Abbott Labs is sued over PediaSure height claims

Abbott Labs is sued over PediaSure height claims Bronx woman sues over Abbott's 'clinically proven' claim Lawsuit says plaintiff's grandson did not gain height By Jonathan Stempel NEW YORK, May 15 (Reuters) - A New York City woman sued Abbott Laboratories ABT.N on Monday, accusing the healthcare company of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase children's height.

Reuters - vor 3 Wochen

Pfizer's India unit posts 3% rise in Q4 profit

Pfizer's India unit posts 3% rise in Q4 profit BENGALURU, May 15 (Reuters) - Pfizer Ltd PFIZ.NS , the Indian unit of U.S. pharmaceutical group Pfizer Inc PFE.N , on Monday reported a 3.1% rise in fourth-quarter profit, helped by lower raw material expenses. Net profit for the quarter ended March 31 rose to 1.30 billion rupees ($15.90 million) from 1.26 billion rupees a year ago, while revenue rose 4.2%.

Konditionen

Beliebte Finanzwerte

Rechtlicher Hinweis: Die Unternehmen der XM Group bieten Dienstleistungen ausschließlich zur Ausführung an sowie Zugang zu unserer Online-Handelsplattform. Durch diese können Personen die verfügbaren Inhalte auf oder über die Internetseite betrachten und/oder nutzen. Eine Änderung oder Erweiterung dieser Regelung ist nicht vorgesehen und findet nicht statt. Der Zugang wird stets geregelt durch folgende Vorschriften: (i) Allgemeine Geschäftsbedingungen; (ii) Risikowarnungen und (iii) Vollständiger rechtlicher Hinweis. Die bereitgestellten Inhalte sind somit lediglich als allgemeine Informationen zu verstehen. Bitte beachten Sie, dass die Inhalte auf unserer Online-Handelsplattform keine Aufforderung und kein Angebot zum Abschluss von Transaktionen auf den Finanzmärkten darstellen. Der Handel auf Finanzmärkten birgt ein hohes Risiko für Ihr eingesetztes Kapital.

Sämtliche Materialien, die auf unserer Online-Handelsplattform veröffentlicht sind, dienen ausschließlich dem Zweck der Weiterbildung und Information. Die Materialien beinhalten keine Beratung und Empfehlung im Hinblick auf Finanzen, Anlagesteuer oder Handel und sollten nicht als eine dahingehende Beratung und Empfehlung aufgefasst werden. Zudem enthalten die Materialien keine Aufzeichnungen unserer Handelspreise sowie kein Angebot und keine Aufforderung für jegliche Transaktionen mit Finanzinstrumenten oder unverlangte Werbemaßnahmen für Sie zum Thema Finanzen. Die Materialien sollten auch nicht dahingehend aufgefasst werden.

Alle Inhalte von Dritten und die von XM bereitgestellten Inhalte sowie die auf dieser Internetseite zur Verfügung gestellten Meinungen, Nachrichten, Forschungsergebnisse, Analysen, Kurse, sonstigen Informationen oder Links zu Seiten von Dritten werden ohne Gewähr bereitgestellt. Sie sind als allgemeine Kommentare zum Marktgeschehen zu verstehen und stellen keine Anlageberatung dar. Soweit ein Inhalt als Anlageforschung aufgefasst wird, müssen Sie beachten und akzeptieren, dass der Inhalt nicht in Übereinstimmung mit gesetzlichen Bestimmungen zur Förderung der Unabhängigkeit der Anlageforschung erstellt wurde. Somit ist der Inhalt als Werbemitteilung unter Beachtung der geltenden Gesetze und Vorschriften anzusehen. Bitte stellen Sie sicher, dass Sie unseren Hinweis auf die nicht unabhängige Anlageforschung und die Risikowarnung im Hinblick auf die vorstehenden Informationen gelesen und zur Kenntnis genommen haben, die Sie hier finden.

Abbott

Nachrichten

Konditionen

Beliebte Finanzwerte

XM Live-Chat